Antiarrhythmic effect of Mercurascan in patients after surgical treatment of ischaemic heart disease.
Premature ventricular contractions are relatively often encountered in patients after surgical treatment of ischaemic heart disease. Mercurascan (MSC), given at 0.05 mg/kg of body weight, favourably affected both the incidence and duration of arrhythmia. Unlike other antiarrhythmics, MSC did not affect the heart rate nor blood pressure. Postoperative treatment of ventricular arrhythmia with MSC is a promising procedure and merits further clinical and experimental investigation.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003327:Coronary Disease / Q000601:surgery; D004341:Drug Evaluation; D005452:Fluoresceins / Q000627:therapeutic use*; D006801:Humans; D008622:Merbromin / Q000627:therapeutic use*; D008991:Monitoring, Physiologic; D011183:Postoperative Complications / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D005452:Fluoresceins; D008622:Merbromin